In a final gesture that closes the books on its attempt to become a “pure-play” biosimilar company, Coherus Biosciences has sold off its pegfilgrastim franchise–its last biosimilar asset–to Intas Pharmaceuticals for $558 million. The move comes as somewhat of a surprise, in that much of the company’s hopes were staked on the revenues to be … Continue reading Coherus Waves Bye Bye to Biosimilars